Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22156293 | 0.86 | HTR7 (0.43) | BRD4OXER1MAPK11MAPK14HTR2C | |
| SCHEMBL6740857 | 0.83 | HRH3 (0.42) | BRD4OXER1MAPK11MAPK14HTR2A | |
| SCHEMBL6741120 | 0.83 | HRH3 (0.41) | HTR2CHTR2AHTR7 | |
| SCHEMBL758075 | 0.81 | MAPK11 (0.38) | BRD4OXER1MAPK11MAPK14HTR2C | |
| SCHEMBL20946399 | 0.81 | HTR2A (0.37) | BRD4MAPK11MAPK14HTR2CHTR2A | |
| SCHEMBL6945213 | 0.79 | LMNA (0.37) | BRD4MAPK11MAPK14HTR2CHTR2A | |
| SCHEMBL11977074 | 0.76 | PTGS2 (0.47) | OXER1MAPK11MAPK14 | |
| SCHEMBL13204941 | 0.73 | HTR2C (0.53) | BRD4MAPK11MAPK14HTR2CHTR2A | |
| SCHEMBL17680481 | 0.72 | AKR1C3 (0.41) | BRD4HTR2CHTR2AHTR7MET | |
| SCHEMBL15712463 | 0.72 | PRKCI (0.44) | BRD4MAPK11MAPK14HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | SPOUT1, MRPL21, NRDC | BRD4 520/4885OXER1 2706/4885CNR1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.